title: [Efficacy and safety of weekly taxol (TXL) for advanced recurrent breast cancer evaluated in a multi-center cooperative clinical trial].
abstract: A multi-center cooperative clinical trial was undertaken to evaluate the safety and efficacy of weekly taxol (TXL) therapy combined with short-premedication as a pretreatment in an effort to determine if TXL can be used in ambulatory treatment. TXL was administered at 60 mg/m2 to patients with advanced recurrent breast cancer once a week without a rest or with a rest for 1 week after treatment for 3 weeks. A total of 36 patients were finally enrolled. The site of recurrence was the local region in 8 patients, lung/pleura in 24, liver in 9, bone in 16, lymph nodes in 15, epicardium in 2, and brain metastasis in 2. The response was CR in 2, PR in 12, NC in 9, PD in 8, and NE in 5, with a response rate of 45.2%. Grade 4 anorexia was reported as non-hematotoxicity. All other adverse reactions, such as myalgia/arthralgia and peripheral neuropathy, were mild (grade 1 or 2). Hematotoxic effects observed in this study included only grade 3 leukopenia in 5 patients, neutropenia in 4, and decreases in hemoglobin in 1.
authors.affiliation: Dept. of Surgery, Kaizuka City Hospital.
authors.forename: Toshio
authors.initials: T
authors.lastname: Nishi
authors.forename: Eiji
authors.initials: E
authors.lastname: Yamanaka
authors.forename: Makoto
authors.initials: M
authors.lastname: Yamasaki
authors.forename: Hajime
authors.initials: H
authors.lastname: Tanaka
authors.forename: Chikara
authors.initials: C
authors.lastname: Takeda
authors.forename: Noriko
authors.initials: N
authors.lastname: Ikeda
authors.forename: Takaya
authors.initials: T
authors.lastname: Hoashi
authors.forename: Jun
authors.initials: J
authors.lastname: Higaki
authors.forename: Teruki
authors.initials: T
authors.lastname: Matsunami
authors.forename: Keiji
authors.initials: K
authors.lastname: Nakano
authors.forename: Masashi
authors.initials: M
authors.lastname: Kogire
authors.forename: Junkou
authors.initials: J
authors.lastname: Furukawa
authors.forename: Nobumasa
authors.initials: N
authors.lastname: Inui
authors.forename: Eiki
authors.initials: E
authors.lastname: Yamauchi
authors.forename: Keiichi
authors.initials: K
authors.lastname: Takagaki
authors.forename: Nobuo
authors.initials: N
authors.lastname: Ogino
authors.forename: Takashi
authors.initials: T
authors.lastname: Nomura
authors.forename: Shinobu
authors.initials: S
authors.lastname: Yamada
authors.forename: Mikio
authors.initials: M
authors.lastname: Fujimoto
authors.forename: Mikihiro
authors.initials: M
authors.lastname: Uenishi
authors.forename: Eiji
authors.initials: E
authors.lastname: Yayoi
mesh_terms: D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000009:adverse effects; D001943:Breast Neoplasms / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009503:Neutropenia / Q000139:chemically induced; D017239:Paclitaxel / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel